Quality Evaluation Of Chinese Community-acquired Pneumonia Guidelinesandpharmacoeconomic Evaluation For Empirical Anti-infectionregimens Of Non-severe Community-acquired Pneumonia In Adults

ObjectiveThis study used AGREE ? tools to evaluate quality ofcommunity-acquired pneumonia guidelinein China then promote guide qualityand improve clinical adherence to guidelines.To do pharmacoeconomic evaluation for empirical anti-infection regimens of non-severe community-acquired pneumonia in adults,andStandardize the diagnosis and treatment process increase the dosage regimen of economy,help the reasonable allocation and use of medicine and health care expenses,improve the effect of the cost,to provide patients with safe,effective,economic and reasonable medical services,maximize utility drug resources.Methods(1)computer retrieval Chinese database including CNKI,Wangfan and VIP.Chinese word retrieval including community-acquired pneumonia,pneumonia,guide.By two independent press into and exclusion criteria,using the designed data extracted form independent screening and extract into the literature data.Usingsomething ? tool evaluation methodological quality of guidelines.(2)to consult between January 2015 and December 2015,the hospital respiratory medicine ward,community-acquired pneumonia,according to diagnostic criteria for comprehensive treatment and complete the clinical path of patients with community-acquired pneumonia.Divided into 6 groups,group A1 to piperacillin sodium he thiazolebajotham sodium treatment;A2 group in the treatment of sodium cefoperazone sodium shuba temple;B1 group for levofloxacin treatment;B2 group of moxifloxacin treatment;Cephalosporins he totally azithromycin treatment for C1 group;For the cefoxitin C2 group Azithromycin treatment.Respectively from the clinical curative effect,laboratory examination indexes,pathogen cleared from three aspects the solution treatment effect,and cost effect analysis methods of antimicrobial therapy drugs are analyzed.Python3.6 as modeling analysis tools at the same time,respectively to the incremental costs and incremental effect of multiple regression analysis,calculating the incremental cost of effect than of the program.Results(1)5 guide overall quality is not high,1 piece for class B,the rest are C level.Something ? six areas as the scope and purpose with the highest scores(64.59%),followed by expression of clarity(48.61%),participants(45.14%),making the rigour of(13.54%),applied(3.12%),the lowest score for editornal independence(0.00%).(2)Six treatments all have good treatment effect and bacterial clearance,including piperacillin sodivun sodium group he azole,cefoperazone sodium sodium group shuba,levofloxacin,moxifloxacin,cephalosporins he organism of cefoxitin+ +azithromycin group,azithromycin clinical effective rate were 98.11%,96.30%,94.29%,98.63%,96.15%,98.28%,it had no statistically significant difference(P>0.05);The bacterial clearance rate was 82.14%,88.24%,92.31%,86.11%,80.65%,71.43%,and the difference was not statistically significant(P>0.05).The cost of treatment was 4579.40±1248.47,7132.2412276.89,3497.39±906.10,5737.47±1481.13,4836.77±1435.21,5198.30 ±1548.58the difference was statistically significant(P<0.05).The cost-effectiveness analysis method was used to analyze the pharmacoeconomics,and the effect ratio of the six components was 4667.62,7406.27,3709.18,5817.17,5030.44,5289.28,and the effect of levofloxacin was the lowest.After sensitivity analysis,the results showed that the pharmacoeconomic analysis results were stable.Through regression analysis on the effect of incremental costs and incremental effect of levofloxacin group of incremental cost is the lowest,consistent with the results of cost-effectiveness analysis.Conclusion(1)Domestic guide formulation and updates should be strictly in accordance with the WHO guidelines for the principles and requirements,something ? scoring criteria,attaches great importance to the improvement of rigor,editorial independence and applied in order to improve the methodological quality of guidelines.(2)Treatment of community-acquired pneumonia clinical pathway,piperacillin sodium sodium group he azole,cefoperazone sodium sodium group shuba,levofloxacin,moxifloxacin,cephalosporins he organism cefoxitin ++ azithromycin group,azithromycin six anti-infection treatment efficacy.The cost effect analysis and regression analysis on the effect of incremental costs and incremental levofloxacin group more economic than other five kinds of treatments.